Articles

Vandetanib First Drug Indicated for Medullary Thyroid Cancer

FDA Approvals, News & Updates

June 2011, Vol 2, No 3

The US Food and Drug Administration (FDA) approved the orphan drug vandetanib (trade name pending; AstraZeneca), a tyrosine kinase inhibitor, for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease.

Peginterferon Alfa-2b for Metastatic Melanoma after Definitive Surgical Resection

FDA Approvals, News & Updates

April 2011, Vol 2, No 2

Sorafenib Active Third-Line in Refractory GIST

By Caroline Helwick

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Hypertension a Good Sign in Patients Receiving Sunitinib

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Future of Colorectal Cancer Therapy: Novel Targeted Pathways

By Caroline Helwick

Colorectal Cancer, Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Competing Tests for Colorectal Cancer Risk Recurrence

By Caroline Helwick

Colorectal Cancer, Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Making Cancer Drugs Worth the Cost

By Christin Melton

HOPA Conference

April 2011, Vol 2, No 2

The Value of EHR Best Practices for Leading Oncology Networks

By Gerard M. Nussbaum; Laura K. Rehfeld

April 2011, Vol 2, No 2

Cancer Drugs and Life Expectancy Focus of Health Economist

Cancer Drugs, Personalized Medicine

April 2011, Vol 2, No 2

ODAC Supports Tightening Up Accelerated Approvals for New Cancer Drugs

By Daniel Denvir

Health Policy, Policies & Guidelines

April 2011, Vol 2, No 2

Page 316 of 329